Trial results

Can Fat-Burning Shots Boost Fertility? Comparing Weight-Loss Injections vs. Healthy Habits for Obese Men With Low Sperm Health

NCT07179120 on ClinicalTrials.gov · last registry update 2025-09-17

Registered but never opened — and the completion date on file, 12 August 2026, has already passed. Its estimated completion date, 12 August 2026, has passed with no update to the record. Primary outcome, as filed: Change from Baseline in Sperm Concentration (million/mL) at Week 32 of Intervention. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status

NOT_YET_RECRUITING

Phase

P2

Drug

semaglutide

Wegovy, Ozempic, Rybelsus

Sponsor

First Affiliated Hospital of Wenzhou Medical University

Sponsor type

Other

Enrollment

180

Started

2026-05-01

Primary completion

2026-08-12 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change from Baseline in Sperm Concentration (million/mL) at Week 32 of Intervention

Conditions studied

Obesity-related Male Infertility

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.